Tipping the balance
Almost four in ten serious adverse drug reactions now listed in the labels of 12 targeted cancer therapies were not mentioned in the studies that led to their approval. Half the serious reactions that were [more]
progress
Goodbye or arrivederci?
Our new vocabulary gene, genome, molecular, targeted, personalised no longer inspires the confidence it once did, and as the cancer community prepares to gather at the 18th ECCO – 40th ESMO European Cancer [more]
Asking the dumb questions
It took ten years of immersion in the world of cancer research to produce the book that won Clifton Leaf a Best Cancer Reporter Lifetime Achievement award. But it started from a simple question: how [more]
Change must come from within
Is progress against cancer is being stifled because young researchers are obliged to spend their best years competing for grants within a system biased against innovation? Half a century ago, a man named Denis Burkitt [more]
Five steps to putting innovation at the heart of cancer care
With health budgets flat-lining and demand for healthcare rising, the only way Europe can improve patient outcomes is by finding new ways to do things better. But who will champion innovation in cancer care and [more]